{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344571","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2026-08-11T20:04:40+00:00","discovered_at":"2026-08-11T20:06:00.542478+00:00","generated_at":"2026-08-11T20:06:36.949412+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Achieve Life Sciences Q2 net loss $74.8M, closes $354M raise, plans NDA resubmission Q4 2026","bullets":["Q2 net loss $74.8M incl $48.7M non-cash warrant fair-value charge; cash $187.3M at June 30, 2026.","Closed $354M private placement ($180M upfront; $174M warrants exercisable before/up to 20 days after FDA approval).","FDA CRL June 20, 2026: no efficacy/safety issues; cGMP and labeling only; NDA resubmission Q4 2026, potential approval H1 2027.","New CEO Andrew D. Goldberg; six new board members; commercial hires from Verona Pharma (Ohtuvayre launch team).","ORCA-OL 52-week safety data presented; ORCA-2/3 cancer subgroup: 24.4% vs 15.8% placebo abstinence."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344571","json":"https://secwatch.observer/filing/0001193125-26-344571.json","markdown":"https://secwatch.observer/filing/0001193125-26-344571.md","text":"https://secwatch.observer/filing/0001193125-26-344571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000119312526344571/0001193125-26-344571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000119312526344571/achv-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:06:36.949412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}